Argenx reports third quarter 2023 financial results and provides business update

$329 million in third quarter global net product sales on track to submit vyvgart® hytrulo sbla for cidp by year-end 2023 results from the advance-iv study published in the lancet management to host conference call today at 1:30 pm cet (8:30 am et) october 31, 2023 amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2023 financial results and provided a business update and outlook for the remainder of the year. “we continue to prioritize patient impact with vyvgart and vyvgart hytrulo, broadening our two gmg products into earlier treatment lines and new geographies.
ARGX Ratings Summary
ARGX Quant Ranking